Renbok phenomenon and contact sensitization in a patient with alopecia universalis.
BACKGROUND
Immune responses are largely regulated by cytokines that are secreted by activated T cells. Interactions among these cells are complex, and the interaction between 2 responses may alter the effect of either response alone. It has been established that contact sensitization-induced inflammation can reverse hair loss due to alopecia areata. In parallel, the Renbök phenomenon demonstrates how 2 distinct autoimmune diseases--psoriasis and alopecia areata--interact to result in clinically active psoriasis suppressing alopecia areata.


METHODS
We describe a patient with concurrent psoriasis and alopecia universalis with terminal hairs within plaques on his extremities, representing the only normal hair growth on his body. Adjacent biopsy specimens confirmed our clinical suspicion of plaque psoriasis with normal hair follicles and alopecia universalis with a peribulbar lymphocytic infiltrate. Our patient's psoriatic plaques cleared rapidly with narrow-band UV-B phototherapy, but hair growth at the site was maintained. His scalp alopecia responded to squaric acid dibutylester contact sensitization therapy.


CONCLUSIONS
This case represents a natural experiment in which 3 distinct but overlapping immune responses favored psoriasis or contact dermatitis over alopecia areata. The precise mechanism responsible for these effects remains unclear; however, based on recent reports, we speculate that cytokine cross-regulation plays a role in competition among these distinct immune responses.
Harris
John E
JE
Department of Dermatology, Hospital of the University of Pennsylvania, 3600 Spruce St, 2 Maloney Bldg, Philadelphia, PA 19104, USA. john.harris@uphs.upenn.edu
Seykora
John T
JT
Lee
Robert A
RA
D000328:Adult; D000506:Alopecia Areata / Q000150:complications* / Q000473:pathology / Q000628:therapy; D003877:Dermatitis, Contact / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000150:complications* / Q000473:pathology / Q000628:therapy
J Exp Med. 1989 Dec 1;170(6):2081-95
2531194
Cell. 2007 Apr 6;129(1):33-6
17418783
Dermatology. 2000;201(1):49-50
10971061
Nat Med. 2003 Jan;9(1):40-6
12461524
Clin Exp Dermatol. 2007 May;32(3):320-1
17263782
Am J Pathol. 2008 Mar;172(3):650-8
18245811
J Clin Invest. 2007 Aug;117(8):2019-27
17671634
Immunol Rev. 2008 Dec;226:132-46
19161421
J Investig Dermatol Symp Proc. 2003 Jun;8(1):12-7
12894988
Eur J Dermatol. 2006 Sep-Oct;16(5):537-42
17101475
J Invest Dermatol. 1994 Oct;103(4):530-3
7930677
J Exp Med. 2006 Nov 27;203(12):2577-87
17074928
Nat Immunol. 2005 Nov;6(11):1133-41
16200068
Blood. 2008 Sep 1;112(5):1557-69
18725574
Dermatology. 2005;210(3):227-8
15785052
Nat Immunol. 2005 Nov;6(11):1123-32
16200070
J Eur Acad Dermatol Venereol. 2003 Jan;17(1):50-2
12602969